# Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

> **NCT02819479** · PHASE2 · COMPLETED · sponsor: **Norton Healthcare** · enrollment: 10 (actual)

## Conditions studied

- Radiation Necrosis

## Interventions

- **DRUG:** 25% Mannitol
- **DRUG:** Low-dose Intra-arterial Bevacizumab

## Key facts

- **NCT ID:** NCT02819479
- **Lead sponsor:** Norton Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-23
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-06-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819479, "Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02819479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*